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Introduction: Reduced postoperative pain is one of the many factors that have driven the growing
emphasis on the role of laparoscopic surgery for surgical management. Several studies have documented
the advantages of the laparoscopic repair of ventral hernias compared to the open ventral herniorraphy.
However, the laparoscopic approach may be associated with more postoperative pain initially. In this
preliminary study, we present data from our early experience with the use of a lidocaine patch for pain
control in the immediate postoperative period following laparoscopic ventral hernia repair (LVH).
Methods: Thirty consecutive patients underwent laparoscopic ventral herniorraphy (LVH) and were
selected randomly and placed into one of two groups. In one group, we placed a lidocaine patch (LP)
(Lidoderm, Endo Pharmaceuticals, Inc., Chadds Ford, PA) on the anterior abdominal wall corresponding
to the placement site of the underlying mesh in ﬁfteen patients (Group A). In the second group, we did
not place a LP on the abdominal wall of ﬁfteen consecutive patients (Group B). We assessed all patients
according to their demographic data, Body Mass Index (BMI), American Society of Anesthesiologists
(ASA) score, the size of the abdominal wall defect (AWD), area of mesh (size) used, operative time, length
of hospital stay (LOA), morbidity, and the individual patient’s pain score at discharge, two weeks and two
months postoperatively.
Results: The two groups were similar with respect to demographics, BMI, ASA, AWD, size of mesh, LOS
and morbidity. Group A had a statistically signiﬁcant reduction in their postoperative pain score at
discharge when compared to Group B (3.13 1.68 and 4.8 1.42, respectively, p value¼ 0.0067).
Conclusion: In this preliminary study, the use of a lidocaine patch in the management of postoperative
pain following laparoscopic ventral herniorraphy is a safe and promising modality to consider in the
management of postoperative pain control.
Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
Reduced postoperative pain is one of the many factors that have
driven the growing emphasis on the role of laparoscopic surgery for
surgical management. Several studies have documented the
advantages of the laparoscopic repair of ventral hernias compared
to the open ventral herniorraphy. For example, the laparoscopic
approach reportedly has fewer complications and a signiﬁcantly
lower recurrence rate than the traditional open ventral hernior-
raphy.1–3 However, in contrast to other laparoscopic procedures,
laparoscopic ventral herniorraphy (LVH) may be associated with
more postoperative pain in the immediate postoperative period
than that following the open approach.1,4 We present data in this
pilot study that examines the effectiveness of the use of the topical: þ1 269 337 6441.
.
Ltd on behalf of Surgical Associateapplication of a 5% lidocaine patch (LP) (Lidoderm, Endo phar-
maceuticals, Inc., Chadds Ford, CA) for pain control in the imme-
diate postoperative period following laparoscopic ventral
herniorraphy.2. Methods
After IRB approval, we randomly assigned thirty consecutive
patients undergoing laparoscopic ventral herniorraphy to one of
two equal groups.
 Group A: Patients received routine postoperative analgesia
(RPA) and/or narcotic either on demand or as needed per the
judgment of the health care provider. In addition, a 5% lido-
caine patch (LP) (Lidoderm) was placed externally on the
anterior abdominal wall of each assigned patient in a location
that corresponded approximately to the location of thes Ltd.
Table 2
Pain score comparison between the two groups
Pain score Group A (with patch) Group B (without patch) p value
At discharge 3.13 1.68 4.80 1.42 0.0067a
10–14 days 2.00 1.41 2.93 1.79 0.1245
1–2 months 0.60 0.91 0.53 0.83 0.8358
a Indicates statistically signiﬁcant data.
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12 hours daily for three successive days in each patient
assigned to this group.
 Group B: In this group, patients did not receive the lidocaine
patch but received RPA only.
We assessed all patients according to their demographic data,
Body Mass Index (BMI), American Society of Anesthesiologists
(ASA) score, the size of the abdominal wall defect (AWD), area of
mesh (size) used, operative time, length of hospital stay (LOS),
morbidity, and the individual patient’s pain score at discharge, two
weeks and two months postoperatively. In this regard, Verbal
rating score (VRS) was used, in which patients were asked to
subjectively assess the severity of their pain using a scale from 0 to
10, with 0 representing no pain and 10 representing the most
severe pain.
The postoperative analgesic protocol consisted of oral combi-
nation tablets of 500 mg of acetaminophen and 5 mg hydrocodone
tablet, the patient can take 1 or 2 tablets every 4 h as needed for
pain to a maximum of 8 tablets per day. We also prescribed
morphine 1–4 mg intravenously every 4 h as needed in case the
oral analgesics are not enough or for breakthrough pain.
The two groups were compared using student’s t-test to deter-
mine if there was any signiﬁcant difference between groups.
Descriptive statistics (mean plus and minus standard deviation)
were computed for all variables. Statistical analysis was completed
using SAS Version 9.1 (Cary, NC). A p value< 0.05 was considered
statistically signiﬁcant.3. Operative technique
All surgeries were performed by a single surgeon (A.A.S.) using
the same technique and postoperative protocol.
The laparoscopic technique for ventral hernia repair entails
ﬁxing the mesh with a combination of non-absorbable transfascial
sutures and tacks. Initially we ﬁx the mesh using 4 sutures, one at
each side of the mesh, then a circle of tacks is applied all around the
mesh, with the tacks placed 1 cm from the edge of the mesh and
1–2 cm apart. Then additional transfascial sutures are added
around the mesh 5 cm apart. So the patient will have 8–12 trans-
fascial sutures.54. Results
There was no signiﬁcant difference between the two groups
regarding age, sex, height, weight, BMI, size of the abdominal wall
defect, size of the mesh used, or the operative time (Table 1). There
was a trend suggesting a difference in the mean hospital stay of
group A (1.2 days) and that of group B (2.5 days); but this difference
was not statistically signiﬁcant (p value¼ 0.1421).
There was a statistically signiﬁcant difference between the two
groups regarding their pain scores at discharge, with group ATable 1
Patients characteristics in the two groups
Patient
characteristics
Group A
(with patch)
Group B
(without patch)
p Value
Age (years) 52.33 17.62 51.53 17.08 0.9005
Gender M/F 8/7 10/5 0.4561
BMI 33.93 7.92 36.07 7.59 0.4651
ASA score 2.27 0.80 1.93 0.47 0.1812
Size of defect (cm2) 31.93 75.18 11.67 14.65 0.3217
Mesh area (cm2) 163.93 103.50 144.47 44.16 0.5109
OR time (min) 101.80 65.55 90.47 38.84 0.5691
Length of stay (days) 1.2 0.78 2.5 3.4 0.1421(mean pain score¼ 3.1) reporting less pain than group B (mean
pain score¼ 4.8); p value¼ 0.0067 (see Table 2).
Two weeks following surgery, Group A reported lower pain
scores (mean¼ 2.0) compared to Group B (mean¼ 2.9). However,
this difference did not reach statistical signiﬁcance (p val-
ue¼ 0.1245) presumably due to a lack of power in this pilot study.
Two months following LVH the mean pain scores for both groups
were similar (Group A mean pain score¼ 0.5 and Group B mean
pain score¼ 0.6). There were no side effects attributed to the
lidoderm patch.
Postoperative analgesic requirement was recorded as the
number of tablets consumed by the patient on the ﬁrst day, we also
recorded the total amount of morphine the patient consumed
during the ﬁrst day. These values are shown in Table 3. Group A had
a lower analgesic use but the numbers were not statistically
signiﬁcant.5. Discussion
Postoperative pain following laparoscopic ventral herniorraphy
represents a unique clinical challenge. This pain is attributed to the
pressure of the transfascial sutures on the subcutaneous nerves,6
and the irritation caused by the tacks used to ﬁx the mesh to the
sensitive parietal peritoneum.7 In addition to the above, the
presence of the mesh itself induces cytokine production with
a subsequent inﬂammatory reaction and associated increased
postoperative pain when compared to the traditional suture
repair.8
Traditional postoperative pain medications include non-
steroidal anti-inﬂammatory drugs9 and opioid analgesics.10 These
drugs may be associated with systemic side effects, which limit
their use and dosage. Topical pain medication with minimal
systemic side effects can help improve postoperative analgesiawith
subsequent improvement of patient satisfaction and a potentially
shorter hospital stay. Adjuvant topical pain therapy can decrease
the required dosage of systemic pain medication and thus decrease
the systemic side effects associated with parenteral opioid
analgesia.
Lidocaine is a local anesthetic and a Class IB antiarrhythmic
agent that belongs to the amide group. Its mechanism of action
entails blockade of the fast-acting Na channels with a subsequent
decrease in nerve transmission. It is administered as a local anes-
thetic either by local inﬁltration or by topical application on intact
skin in the form of a cream, gel, or a patch. The lidocaine patch 5%
(Lidoderm, Endo pharmaceuticals, Inc, Chadds Ford, CA) has been
successfully used in the treatment of postherpetic neuralgia11 and it
proved to be beneﬁcial in the treatment of osteoarthritis,12 low back
pain,13 and diabetic polyneuropathy.14 Each patch contains
approximately 700 mg of lidocaine, but only 5% of this dose isTable 3
Analgesic use on the ﬁrst postoperative day
Pain medication Group A Group B p Value
Oral narcotics 6.54 1.2 5.9 1.6 0.752
IV Morphine 13.3 3.4 10.2 4.5 0.459
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the systemic absorption of lidocaine from the patch is minimal with
a mean maximum plasma concentration about 10% of the antiar-
rhythmic dose, which results in the absence of systemic side effects
of lidocaine.15 The only side effect noted with the lidocaine patch
was a mild skin reaction in some patients.16
Many authors have suggested the use of various types of local
anesthesia to decrease postoperative pain, which include the use of
a rectus-sheath block,10 and local inﬁltration of bupivacaine at
suture sites either preoperative17 or postoperative.18 A single dose
of bupivacaine (a short acting local anesthetic) can decrease pain up
to two weeks postoperatively. The mechanism for or the cause of
this prolonged effect is unexplained.18 Data from this preliminary
study suggests a similar ﬁnding with the use of a lidocaine patch.
Other topical local anesthetic preparations containing lidocaine
include EMLA (lidocaine–prilocaine cream), which is currently used
to decrease the pain of injections in children.19 EMLA has been tried
also as a method to decrease the pain associated with minor
procedures such as hystrosalpingography,20 and dental proce-
dures.21 However, its effect is short lived and of limited efﬁcacy.
In conclusion, the use of a lidocaine patch in the management
of postoperative pain following laparoscopic ventral herniorraphy
appears to be safe and feasible. This promising modality repre-
sents a potential adjuvant therapy that may decrease the
requirement for systemic analgesia needed postoperatively, and
thus may minimize their side effects. Theoretically, this might
translate into a shorter hospital stay and a more rapid recovery. A
prospective randomized controlled double blinded study with
a larger sample size is needed to conﬁrm the results of this pilot
study before the use of a lidocaine patch following ventral her-
niorraphy can be widely recommended.Conﬂict of interest
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